Travers Smith advises long standing clients Silverfleet Capital and the founder shareholders on the sale of Aesica Pharmaceuticals
A Travers Smith team led by private equity partner Helen Croke advised long standing clients Silverfleet Capital, and the founder shareholders of Aesica Pharmaceuticals Limited, on the proposed sale of Aesica to Consort Medical plc for £230 million.
Established in 2004, Aesica has grown both organically and through acquisitions and is one of Europe's leading pharmaceutical contract development and manufacturing organisations. It currently employs approximately 1,250 people and has six pharmaceutical development and manufacturing sites in the UK, Germany and Italy.